

Evaluation Report

Final Decision: Reconsider for Evaluation after Modifications and Clarifications

Article No.: 101171-IJCR-AJ

Article Type: Research Article

Figures Available: 1 Figure Cited: 1

Table Available: 4 Tables cited: 4

Manuscript falls in the scope of the journal? **Yes** No**My observations/comments about this article are:**

No.	Part	Comments	Author Response
1	Cover letter	Overall Ok	
2	Write up	Overall Ok	
3	Title	Main title is the major component of a research article to attract the readers and increase the readership that's why title of research article should be effective, simple and concise (within 14 words). It should indicate accurately the purpose of the study. Author is requested to rewrite an attractive main title.	Anticancer activity of Linamarin from Cassava Leaves (Manihot esculenta Cranz) on Raji Cells
4	Running Title	Overall Ok	
5	Author's Information	Overall Ok	
6	Author's Contribution	Overall Ok	
7	Abstract	Overall Ok	
8	Keywords	Overall Ok	
9	Introduction	Overall Ok	
10	Materials and Methods	Please indicate both the manufacturer's name and location (including city, state, and country) for all specialized equipments, kits, software, incubators, instruments, pH meter,	MTT reagent (Sigma Aldrich, Darmstadt, Germany), laminar air flow (Nuarie), incubator (Nuarie), phase contrast microscope (Olympus, Japan), electric scales (Sartorius),

Anticancer Activity of Linamarin on Raji

		and reagents used in the experiment.	micropipette (Socorex), centrifuge (B. Braun biotech Internasional), vortex (Genie), waterbath (Labec), pH meter (TOA), Tissue Culture Flask (TCF) 25 cm ² (Nunclone), microplate 96 (Nunclone), hemocytometer (Neubauer), filter millipore 0,2 um (Labec), fluorescence microscope (Olympus, Japan), glass object (Sigma Aldrich), deck glass (Sigma Aldrich), light microscope (Olympus, Japan).
11	Results) Overall Ok	
12	Figures) Author is advised to label the figure 1 correctly by which a reader can easily understand the results obtained in figure 1.	Ok
13	Tables) This value is not present in table 1. Author is advised to provide the correct value in table 1, in its description and discussion.	Ok
14	Discussion) Overall Ok	
15	Conclusion) Overall Ok	
16	Acknowledgement) Overall Ok	
17	Significance Statement) Overall Ok	
18	References) Author is advised to Provide DOI or URL of all listed references.	Ok

- 13 **Guidelines to attend the Comments:**
- 14 N Author is requested to please highlight the amended portion in the manuscript. It will be more helpful for us in cross checking of suggested
- 15 modifications.
- 16 N Please give your response in the Evaluation report as well under the column “**Author Response**” for all the parts of the manuscript.
- 17 N Incorporate all the recommended modifications in their respective sections throughout the manuscript.

Anticancer Activity of Linamarin on Raji

18 **Plagiarism checked**
19 **101171-IJCR-AJ**

20 Research Article

21 **Anticancer Activity of Linamarin from Cassava Leaves**

22 **(*Manihot esculenta* Cranz) on Raji Cells**

24 Dwi Sutningsih^{1*}, Mohamad Arie Wuryanto², Henry Setyawan Susanto³, Sujud Hariyadi⁴,

25 Mustofa⁵

26 ^{1.} Department of Epidemiology and Tropical Disease, Faculty of Public Health, Diponegoro
27 University, Semarang, Indonesia, E-mail: dwisuti98@gmail.com

28 ^{2.} Department of Epidemiology and Tropical Disease, Faculty of Public Health, Diponegoro
29 University, Semarang, Indonesia, E-mail: arie.epid@gmail.com

30 ^{3.} Department of Epidemiology and Tropical Disease, Faculty of Public Health, Diponegoro
31 University, Semarang, Indonesia, E-mail: henrysmg@gmail.com

32 ^{4.} Department of Epidemiology and Tropical Disease, Faculty of Public Health, Diponegoro
33 University, Semarang, Indonesia, E-mail: hariantosudjut@yahoo.com

34 ^{5.} Department of Pharmacology, Faculty of Medicine, University of Gadjah Mada,
35 Yogyakarta, Indonesia, E-mail : mustofafk@ugm.ac.id

36
37 ***Correspondence:** Dwi Sutningsih, Department of Epidemiology and Tropical Disease

38 Faculty of Public Health, Diponegoro University, Semarang, Indonesia, Phone / Fax: +62

39 247460044, Email: dwisuti98@gmail.com

40 LiveDNA*: 62.16151

41 **Author contributions**

42 Dwi Sutningsih: Performed literature review, developed research proposal, conducted
43 experiments and data analysis, and wrote manuscript.

44 Mohamad Arie Wuryanto: Participated in research design and manuscript writing.

45 Henry Setyawan Susanto: Reviewed research proposal and contributed to cytotoxic
46 examination and data analysis.

47 Sujud Hariyadi: Participated in data analysis and contributed to manuscript writing.

48 Mustofa: Conducted the experiments and wrote the manuscript.

Commented [WU1]: Main title is the major component of a research article to attract the readers and increase the readership that's why title of research article should be effective, simple and concise (within 14 words). It should indicate accurately the purpose of the study. Author is requested to rewrite an attractive main title.

49

50 **ABSTRACT**

51 **Background and Objective:** Linamarin is a active compound isolated from the leaves of
52 cassava (*Manihot esculenta*Cranz) that has a cytotoxic effects on HT-29, MCF-7, and HL-60
53 cells. This study aims to determine the cytotoxic and antiproliferation activity and induction
54 of p53 protein in Raji cells after administration of various concentrations of linamarin from
55 cassava leaves (*Manihot esculenta* Cranz).

56 **Materials and Methods:** Linamarin was isolated from cassava leaves (*Manihot*
57 *esculenta* Cranz) using a multilevel purification method. Linamarin cytotoxicity was tested on
58 Raji cells using the MTT method, while antiproliferation activity was tested using a *doubling*
59 *time* test. P53 protein expression was observed by immunocytochemical tests. The cytotoxic
60 activity of Raji cells was expressed by the value of concentration 50. The *doubling time*
61 was calculated by comparing the *slope* values of the log graphs of the number of cells at
62 various times. Raji cells that were positive for p53 protein showed brown painted nuclei or
63 cytoplasm.

64 **Results:** Linamarin from cassava leaves can inhibit cytotoxic activity and proliferation on
65 Raji cells. The higher the linamarin concentration, the longer the doubling time of Raji
66 cells. The expression of p53 protein on Raji cells after linamarin administration was higher
67 than the control. P53 protein expression was found in the nuclei (91.05%) and cytoplasm
68 (8.95%).

69 **Conclusions:** Given those findings, linamarin from cassava leaves has the potential to be
70 developed as an anticancer agent.

71

72 **Keywords:** Linamarin, *Manihot esculenta* Cranz, cytotoxic, antiproliferative, p53 protein,
73 Raji cells

74 **INTRODUCTION**

75 Obstacles and side effects caused by various cancer treatments have necessitated the
76 discovery of highly effective alternatives with minimal side effects. One such effort is the
77 development of drugs from plants that contain anticancer compounds. The development of
78 cancer drugs from plants has several advantages, among which are their low cost, availability,
79 and relatively few side effects¹.

80 In Indonesia, cassava has considerable economic value compared to other tubers. Not
81 only is cassava (*Manihot esculenta* Cranz) one of the world's principal food staples after
82 grains and corn, ¹ their leaves, widely consumed in Indonesia and
83 elsewhere, are rich in vitamins A, C, K, among others, and minerals, including iron, calcium,
84 and phosphorus. The energy content of cassava leaves is greater than most other green
85 vegetables ². Cassava also contains cyanogenic glucoside compounds, which consist of
86 linamarin and lotaustrain at a ratio of 10:1 ^{3,4}. Linamarin has potential use as an anti-
87 neoplastic compound^{5,6}. The mechanism of linamarin in the treatment of cancer using
88 linamarase gene therapy has been investigated by Cortes in 2002.

89 Meanwhile the Idibie ⁶ study states linamarin in root tubers has been proven in
90 vitro to have cytotoxic effects on HT-29, MCF-7, and HL-60 cells. From the results of this
91 study, Inhibitor Concentration 50 (IC₅₀) was obtained in the amounts of > 300 µg/ml, 235.96
92 ± 9.87 µg/ml, and 246.51 ± 10.12 µg/ml after incubation for 48 hours. In this study, linamarin
93 was obtained from cassava leaf extracted with methanol. The study of Yusuf *et al.* ⁷ using
94 linamarin isolated from cassava leaves also showed cytotoxic effects on Caov-3 cells and
95 Hela cells. The IC₅₀ value of the two cell lines is 38 µg/ml and 57 µg/ml respectively. Cancer
96 cell death has been caused by the linamarin content found in cassava plants⁸⁻¹¹. Carotene and
97 vitamin C compounds found in cassava leaves are thought to have anticancer properties¹²⁻¹⁵.
98 Research by Enger *et al.*¹⁶, stated that carotene is protective toward colon adenoma rather than

Anticancer Activity of Linamarin on Raji

99 other carotenoids in the early stages of tumor formation. Kontek *et al.*¹⁷ stated that vitamin C
100 had a positive effect on the damage level of oxidative DNA in colon cancer cells.

101 The benefits of cassava as an anticancer agent have been proven in several cancer cells,
102 but have not yet been widely studied regarding its potential in Raji cells. This study aimed to
103 determine cytotoxic and antiproliferative activity and induction of p53 protein in Raji cells
104 following treatment of linamarin from cassava leaves.

105

106 MATERIALS AND METHODS

107 Cassava leaves (*Manihot esculenta* Cranz) were obtained from the local market in
108 Yogyakarta, Indonesia, then identified at the Laboratory of Pharmaceutical Biology, Faculty
109 of Pharmacy, Gadjah Mada University. This research project was conducted from June 4,
110 2018 to December 4, 2018. Raji cells were obtained from the collection of the Laboratory of
111 Parasitology, Faculty of Medicine, Gadjah Mada University. This cell is a continuous cell line
112 that grows floating, similar to lymphoblast cells (B lymphocytes) from Burkitt's
113 lymphoma infected by Epstein-Barr Virus (EBV). Materials for growing Raji cells are RPMI
114 solution (Sigma-Aldrich), Dulbecco's Modified Eagle's Medium (DMEM) (Sigma-Aldrich),
115 HEPES, Fetal Bovine Serum (FBS)(Gibco), penicillin-streptomycin(Gibco), DMSO (Sigma-
116 Aldrich), tripan blue (E-Merck), and 3-(4-, 5 dimethylthiazol-2-yl) -2.5-diphenyl tetrazolium
117 bromide (MTT) (Sigma-Aldrich).

118 **Linamarin isolation from cassava leaves:** A 5 g batch of cassava leaves was cut into small
119 pieces, then pounded in a mortar. The result was blended thoroughly with a total of 10 ml of
120 0.1M HCl solution. The mixture solution was centrifuged at 3500 rpm to obtain the
121 supernatant. The supernatant liquid obtained was transferred to the Falcon tube. The
122 supernatant liquid mixture with 0, 1 M HCl was linamarin extract of cassava leaf, which was
123 then isolated. Finally, the linamarin extract was frozen at - 20°C⁸.

Anticancer Activity of Linamarin on Raji

124 **Cytotoxic test on Raji cells:** The cytotoxicity test was done colorimetrically using **MTT**
125 **reagents** (Sigma-Aldrich, Darmstadt, Germany). Linamarin of 10 μL at various concentrations
126 was added to Raji cell culture the day after transplantation. The concentration of linamarin
127 used for treatment of Raji cells was 31.25, 62.5, 125, 250, 500, and 1000 $\mu\text{g/ml}$. Cells that
128 were not treated were used as controls. On the third day, 20 μL of MTT reagent was added to
129 approximately 5 mg/ml per well. After four hours of incubation, 100 μL of 0.1 N HCl-
130 isopropanol was added to each well to dissolve the formazan crystals that had
131 formed. Absorbance (A) was measured using a microplate reader at a wavelength of 595
132 nm. All steps were carried out three times.

133

134 **Antiproliferation test (doubling time) in Raji cells:** Cells were fasted for 24 hours in culture
135 media containing 0.5% of FBS. Afterwards, they were grown in a plate with a medium added,
136 with linamarin at a non-lethal concentration of three series below the IC_{50} value. Then it was
137 incubated in a 5% CO_2 incubator (Nuairie) at 37 $^\circ\text{C}$ for 24, 48, and 72 hours. Each well was
138 calculated by the number of cells living using hemocytometrics (Neubauer).

139

140 **Immuno-cytochemical test in Raji cells:** In a microculture, 96 wells containing 100 μl of
141 test cells, with a density of 2×10^4 cells/well, 100 μl of the test compound were added at
142 concentrations of 10 $\mu\text{g/ml}$. They were then incubated with 5% CO_2 flow at 37 $^\circ\text{C}$ for 24
143 hours. After being incubated overnight, 200 μl of cells from each well were taken and inserted
144 in eppendorf tubes, then centrifuged to 1200rpm x 5 minutes. The supernatant liquid was
145 removed, leaving the pellet, and then re-suspended. The cell suspension was extracted and
146 placed on a glass object that had been coated with poly-lysine. The cells were fixated with
147 acetone for 10 minutes. Later, they were washed with PBS (Phosphate Buffered
148 Saline)(E.Merck) x 5 minutes and etched with hydrogen peroxidase 0,1% for 10

Commented [WU2]: Please indicate both the manufacturer's name and location (including city, state, and country) for all specialized equipments, kits, software, incubators, instruments, pH meter, and reagents used in the experiment.

Anticancer Activity of Linamarin on Raji

149 minutes. After washing them with running water, they were rinsed with PBS for five minutes,
150 dripped with 100 μ l normal horse serum for 10 minutes, and cleaned without water. Finally,
151 they were dripped with anti-p53 protein primary antibodies (Novocastra) and left for 24
152 hours.

153 The next day the suspension was:

154) washed twice with PBS x 5 minutes each;

155) dripped with biotinylated secondary antibodies (Novocastra) x 10 minutes;

156) washed x 2 with PBS x 5 minutes each;

157) dripped then incubated with Avidin Biotin reagent enzyme (Novocastra) x 10 minutes;

158) washed x 2 with PBS x 5 minutes each;

159) incubated with a peroxidase substrate (DAB) (Novocastra) x 10 minutes or until the
160 coloring appeared;

161) washed with running water;

162) counterstained with hematoxylin for 10 to 20 seconds, then washed with running water; and

163) Dehydrated using 95% ethanol and xylen x 10 minutes each.

164) The mounting media was dripped, and then covered with a glass deck.

165 The results were observed under a light microscope (Olympus, Japan)
166 with 400x magnification. Cells positive for p53 protein showed nuclei or cytoplasm painted
167 brown.

168

169 **Data analysis:** Raji cell cytotoxicity was analyzed using probit analysis to determine 50%
170 Inhibition Concentration (IC_{50}). Probit analysis was obtained from the conversion of the
171 percentage of inhibition to the probit value. Percentage of inhibition was calculated
172 as follows:

173 % Cell inhibition = $[(A - B) : A] \times 100\%$

Anticancer Activity of Linamarin on Raji

174 A: The number of living cells in untreated controls

175 B: The number of living cells due to the treatment of compounds at various
176 concentrations

177 The difference in percentages of cell inhibition between each treatment group was
178 tested statistically using a one-way ANOVA test with 95% Confidence Interval. Analysis of
179 doubling times was calculated by comparing the slope of the log graphs of the number of cells
180 at different observation times. To find differences between groups, the average number of
181 cells living at the various times was analyzed statistically using the one-
182 way ANOVA test with a 95% confidence level. Expression of p53 protein was analyzed by
183 observing its percentages as expressed in Raji cells after immuno-histochemical
184 treatment. Cells that were positively stained with p53 protein showed nuclei or cytoplasm
185 painted brown. The proportion of cells that were positively p53 protein was determined by
186 calculating the presence of stained nuclei or cytoplasm per 100 cells.

187

188 **RESULTS and DISCUSSION**

189 **Linamarin cytotoxic activity in Raji cells:** Cytotoxic activity was tested to determine the
190 toxicity of a linamarin compound on Raji cells. Raji cells are continuous cell lines that grow
191 floating and unattached to the bases of flasks. The cell is similar to lymphoblast cells (B
192 lymphocytes) from Burkitt's lymphoma infected by Epstein-Barr Virus (EBV). The cells are
193 round and clustered. Living cells will appear bright under a contrast phase microscope while
194 dead cells will appear dark.

195 The parameters used to express the potency of linamarin toxicity from cassava leaves
196 are IC_{50} values. The results of calculating cell inhibition percentage of Raji cells after
197 linamarin administration from cassava leaves are presented in Table 1. The Table 1. shows
198 that at the highest linamarin concentration (1000 $\mu\text{g/ml}$), the percentage of Raji cell inhibition

Anticancer Activity of Linamarin on Raji

199 was 97.550%, while at the lowest concentration (31.25 μ g/ml), the percentage was 27.194
200 percent.

201 The results of Kolmogorov-Smirnov's analysis showed that the average Raji cell
202 inhibition was normally distributed ($p = 0.135$), while homogeneity test results were
203 homogeneous ($p = 0.088$). The one-way ANOVA test was used to determine the differences
204 in Raji cell inhibition between various linamarin treatments. The results of the one-way
205 ANOVA analysis revealed significant differences between the Raji cell inhibition levels at
206 various linamarin concentrations ($p = 0.000$).

207

208 **Antiproliferation activity of linamarin in Raji cells:** The concentration of the test
209 compound used in the doubling time test was three concentrations below the
210 IC_{50} value (15.63; 31.25; 62.50 μ g/ml). Cell counts are carried out at 0, 24, 48, and
211 72 hours. Raji cells had been previously fasted (starved) for 24 hours using RPMI 1640 media
212 containing FBS 0.5 %. Data of doubling time analysis of Raji cells after linamarin treatment
213 and control (without treatment) can be seen in Table 2.

214 Data from Table 2 shows how the multiplication times of Raji cells after linamarin
215 treatment, at concentrations below the IC_{50} value, run greater than the control
216 times. Linamarin concentration of 62.50 μ g/ml can delay the doubling times of Raji
217 cells by ± 2 x those of the Raji control cells.

218 From Fig. 1, it can be seen that at 30 minutes after the treatment of the test compound,
219 there has been no inhibition of Raji cell growth, in contrast to observations at 24, 48, and 72
220 hours. One-way ANOVA analysis showed that there were significant differences ($p = 0.023$)
221 in the average number of living Raji cells, dependent upon the elapsed time post-
222 linamarin treatment (24, 48, and 72 hours).

223

Anticancer Activity of Linamarin on Raji

224 **Expression of p53 protein on Raji cells:** The immunocytochemical test results showed that
225 linamarin can increase the expression of p53 protein on Raji cells. Complete results of p53
226 protein expression tests are presented in Table 3.

227 According to those results, there is a tendency for greater p53 protein expression in the
228 treatment group compared to the control group. Linamarin concentration of 62.5 µg/ml shows
229 increased positive p53 protein expression in Raji cells by 77.5%, ± 3.07%, while linamarin
230 concentration was 31.25 µg/ml at 40 ± 1.87%.. The one-way ANOVA test results showed a
231 significant difference in the number of p53 protein expression in Raji cells at various
232 linamarin concentrations (p = 0.000). Details pertaining to the expression of p53 protein in the
233 nuclei and cytoplasm of Raji cells are presented in Table 4 and Fig. 1.

234 From Fig.1 it can be seen that in the Raji control cell there was a tendency to decrease
235 the positive p53 protein expression, whereas in the Raji cells with linamarin, 32.5 and 62.5
236 µg/ml concentrations appeared to increase positive p53 protein expression, with most located
237 in the nuclei (Table 4).

238

239 **Linamarin cytotoxic activity in Raji cells:** The cytotoxicity test determined the value of
240 IC₅₀, which is a concentration capable of inhibiting cell growth, such as Raji cells, by up to 50
241 percent. The smaller the IC₅₀ value, the more toxic the compound is. The potential for
242 linamarin toxicity from cassava leaves (*Manihot esculenta* Cranz) to Raji cells is indicated by
243 IC₅₀ values of 71.865 ± 0.229 µg/ml. At its highest concentration (1000 µg/ml), the
244 percentage of Raji cell growth inhibition was 97.550% ± 0.005%, while the lowest
245 concentration of linamarine (31.25 µg/ml) was 27.194 ± 0.096% (Table 1). From Table 1,
246 shows that at the higher the concentration of linamarin, the greater the percentage of Raji cell
247 growth inhibition, with a significant statistical difference (p <0.05). This proves that linamarin
248 obtained from cassava leaves (*M. esculenta* Cranz) can suppress the growth of Raji cancer

Anticancer Activity of Linamarin on Raji

249 cells. Linamarin is found in all parts of cassava plants (*M. esculenta* Cranz), but most
250 abundantly at the roots, leaves, and root tuber skin.⁵

251 Yusuf *et al.*⁷ found that linamarin from cassava leaves can inhibit the growth of Caov-
252 3 cancer cells and Hela cells with IC₅₀ values of 38 µg/ml and 57 µg/ml, respectively. Idibie⁶
253 in his research, stated that IC₅₀ values decreased when pure linamarin compounds and crude
254 extracts of cassava tubers were given along with linamarase enzymes on MCF-7 cancer cells
255 (adenocarcinoma breast cancer), HT-29 (adenocarcinoma colon), and HL-60 (cell line
256 leukemia). Meanwhile, the IC₅₀ values of crude extracts are higher than linamarin if not given
257 along with the linamarase enzyme. Likewise, the results of Alfourjani's study⁵ showed that
258 the IC₅₀ values of MCF cells after treatment with raw cassava leaf extract and boiled cassava
259 leaves were 63.1 and 79.4 µg/ml, respectively.

260 Crude extracts are said to have strong potential as anticancer agents if the IC₅₀ value
261 is less than 30 µg/ml¹⁹. The results of this study showed IC₅₀ value of Raji cells after
262 linamarin administration to be greater than 30 µg/ml. In fact, they registered as high as 71.865
263 ± 0.229 µg/ml, meaning that the potency of linamarin toxicity in active Raji cells was weaker,
264 or only moderately active (30 < IC₅₀ < 100 µg/ml). This was presumably due to differences in
265 the characteristics of cancer cells used in the study.

266 Raji cells are found in the Burkitt's lymphoma cell line in humans. Burkitt's
267 lymphoma at the molecular level is characterized by synergistic Bcl-2 and c-
268 myc expressions. C-myc is upregulation Bcl-2, so the increase in c-myc expression can also
269 increase the expression of Bcl-2. As a result of this increase in expression, cells do not
270 experience apoptosis^{20,21}. Burkitt's lymphoma has chromosome translocation that activates c-
271 myc. In some patients it also shows the occurrence of mutations in p53 which result in the
272 inhibition of the apoptotic process in these cancer cells. Activating p16INK4a resulted in loss
273 of CDK inhibitory function, diminishing loss of cell control of its growth. Changes

Anticancer Activity of Linamarin on Raji

274 (mutations) also occur in the expression of pRb and p53, which are gene suppressor
275 tumors, and in other genes, such as Bax, p73, and Bcl-6, which provide sufficient growth
276 signals and inhibit apoptosis in cancer cells²²⁻²⁴. Mutations also occur in downstream
277 Caspase-3 which causes Raji cells to be resistant to apoptosis^{25,26}.

278 The protein expression of the Epstein-Barr Nuclear Antigen 1 (EBNA1) in Burkitt's
279 lymphoma, infected by Epstein- Barr Virus (EBV), can also inhibit the occurrence of
280 apoptosis in cancer cells²⁷. Through this mechanism, it is suspected that Raji cells can avoid
281 the apoptotic mechanism triggered by linamarin compounds from cassava leaves. This is why
282 the suspected cause of cassava leaf extract cytotoxicity against Raji cells is considered
283 moderate.

284 Linamarin is said to be antineoplastic by its release of HCN during the process of
285 hydrolysis. When HCN is released, the cancer cell is exposed to the lethal cyanide effect
286 released by linamarin. Linamarin is broken down and cyanide is released only in the areas
287 around the cancer cells. This causes gradual cancer cell death. Because normal cells do not
288 have the linamarase gene, they will not be affected^{5,6}.

289 Inhibition of Raji cell growth is also due to β -carotene content in cassava leaves. β -
290 carotene has an anticancer mechanism by its carcinogen-modulating metabolism and
291 antioxidant activity, thus modulating the immune system, increasing cell differentiation,
292 stimulating communication gap cell junctions to cells and affecting retinoid-dependent
293 signals²⁸. β -Carotene is also directly related to inhibition of cell proliferation, increased
294 apoptosis, induces cell cycle arrest¹⁴. In his research, Enger *et al.*¹⁶ stated that β -carotene is
295 protective toward colon adenoma in the early stages of tumor formation. The same thing was
296 determined by Gloria *et al.*,¹⁴ who proved that carotenoids were able to increase breast cancer
297 cell apoptosis.

Anticancer Activity of Linamarin on Raji

298 Inhibition of Raji cell growth by linamarin can also be influenced by vitamin C.
299 Cassava leaves contain vitamin C of 103 mg, higher than other green vegetables¹⁶. Vitamin C is
300 known to act as an antioxidant in preventing infection, helps the absorption of iron and
301 calcium, and is associated with the synthesis of collagen, carnitine, noradrenaline, and
302 serotonin in the body²⁹⁻³². Besides its function, vitamin C also plays an important role in
303 activating genes involved in DNA repair, as well as modulating DNA damage in ROS-
304 affected cells. The results of the Kontek *et al.*¹⁷ study prove that vitamin C has
305 a positive effect on the level of oxidative DNA damage. Vitamin C provides a protective effect
306 for normal tissue to counteract the activity of toxic substances and their
307 metabolites, thus affecting the extent of colon cancer cell inhibition^{33,34}.

308
309 **Antiproliferative activity of Raji cells:** Analysis of cell proliferation inhibition can be done
310 by the doubling time test. Compounds that delay the multiplication times of cells can inhibit
311 genes or proteins that regulate the cell cycle. The doubling time test is done by counting the
312 number of cells treated in a time unit (e.g., 24 hours). Each sample is calculated by a
313 hemocytometer, and then a curve with cell number versus incubation time is
314 made. Differences in cells' doubling times can be determined from the slope of the curve or
315 calculated by extrapolation³⁵. Raji cells were previously fasted (starved) for 24 hours using
316 RPMI 1640 media containing FBS 0.5 percent. Reducing this growth signal is necessary
317 because it reduces the speed of cell growth, which causes the cell to be in the same initial
318 start, or G0 phase. Without fasting when treated, the cells remain in different phases
319 which makes it difficult to observe the inhibition properties of linamarin on cell cycle
320 progression³⁶.

321 From Table 2 it can be seen that the doubling time value of Raji cells with linamarin
322 treatment concentrations of 62.5 µg/ml is greater than the doubling time value of Raji cells

Anticancer Activity of Linamarin on Raji

323 with linamarin treatments of 32.5 µg/ml and 15.63 µg/ml. This is supported by the linamarin
324 curve slope value of 62.5 µg/ml, which is smaller than the linamarin slopecurve of the
325 treatment with 32.5 µg/ml and 15.63 µg/ml. This means that linamarin 62.5 µg/ml has a better
326 chance of postponing cell doubling time of Raji cells than linamarin 32.5 µg/ml and 15.63
327 µg/ml. It is suspected that the linamarin in cassava leaf extract can inhibit genes or proteins
328 that regulate cell division. It may inhibit signal transduction through inhibition of growth
329 signals or through inhibition of cell cycle progression by inhibiting proto-oncogenes such as
330 CycD, cdk 4/6 and c-myc. Similarly, it may activate suppressor tumors such as caspase 3/8/9,
331 p53, pRb, and Bcl2 inactivation^{5,6}.

332 The data in Table 2 shows that the doubling time value of Raji cells with linamarin
333 treatment concentrations of 62.5 µg/ml is twice the doubling time value of Raji cells without
334 treatment (control). This means that linamarin concentration of 62.5 µg/ml can cut the
335 doubling time of Raji cells to half that of Raji cells doubling times without treatment
336 (control). The price of doubling time for linamarin treatment is greater than that for control.
337 This indicates that linamarin has the ability to inhibit Raji cell proliferation and possess
338 cytotoxic activity. The higher the linamarin concentration, the longer the doubling time of
339 Raji cells. A linamarin construction of 31.25 µg/ml can inhibit cell proliferation better than
340 linamarin 15.63 µg/ml. This inhibition may occur in signal transduction through inhibition of
341 growth signals or through inhibition of cell cycle progression by inhibiting proto-oncogenes
342 such as CycD, cdk 4/6, and c-myc. Or, it may be able to activate suppressor tumors such as
343 caspase 3/8/9, p53, pRb, and Bcl2 inactivation^{37,38}.

344
345 **Expression of p53 protein in Raji cells with linamarine treatment:** Immunocytochemical
346 analysis is intended to determine the expression of p53 protein in Raji cells. In this study
347 antibodies can be used to detect both wild and mutant type p53 proteins in cancer

Anticancer Activity of Linamarin on Raji

348 cells. Positive expression of p53 protein is indicated by brown color in the cell nucleus or
349 cytoplasm; wild or mutant types cannot be distinguished. The results showed that linamarin
350 could increase the expression of p53 protein in Raji cell. Linamarin concentrations of 62.5
351 $\mu\text{g/ml}$ can increase positive p53 protein expression ($77.5 \pm 3.07\%$) greater than linamarin
352 $31.25 \mu\text{g/ml}$ ($60\% \pm 1.87\%$) (Table 1). In Raji control cells or with linamarin treatment from
353 cassava leaf extract, most p53 protein expressions are located in the cell nucleus, although
354 some are located in the cytoplasmic part (Table 3). The control cells also shown have positive
355 p53 protein expression but the amount was less than the treatment with linamarin
356 concentrations of $31.25 \mu\text{g/ml}$ and $62.5 \mu\text{g/ml}$ (Fig.1). This shows that Raji cell
357 death occurred through the mechanism of inhibition of Raji cell proliferation, by
358 activating suppressor gene tumors such as p53. The presence of stress or DNA damage
359 can spur the expression of p53 protein in Raji cells³⁹.

360 The increase in p53 protein expression in Raji cells after the linamarin treatment
361 proved several possibilities: first, the increase was an increase in wild type p53
362 expression. P53 protein is encoded by p53 tumor suppressor genes and has an important role
363 in cell regulation and proliferation²². The wild type of p53 protein is expressed very little in
364 normal conditions, but there will be an increase in response to normal cells if there is DNA
365 damage⁴⁰. Increased expression of wild-type p53 will be activated through the p21 protein to
366 stop DNA replication and cell division when DNA damage occurs. This happens because an
367 increase in p53 protein will stimulate p21 gene transcription. The p21 protein is an inhibitor
368 of CDK and has the ability to inhibit phosphorylation of pRB, thus blocking the release of
369 E2F transcription factors and DNA replication. However, if DNA damage is too severe and
370 cannot be repaired, p53 will induce apoptosis by stimulating Bax transcription, which will
371 then inhibit the activity of the Bcl2 gene⁴¹. The Bcl2 gene functions to inhibit the response of
372 apoptosis to various cell types caused by various stimulations related to apoptosis. Thus, p53

Anticancer Activity of Linamarin on Raji

373 plays an important role in preventing the accumulation of cells with DNA abnormalities that
374 can mutate into cancer cells⁴².

375 If the p53 expression is the wild type, then DNA damage will cause a rapid rise in p53
376 protein expression, thus inducing a resting phase of the cell cycle during the G1 phase. Wild-
377 type p53 will cause a cessation of growth in the G1 phase,⁴³ thus providing sufficient time for
378 the DNA repair genes such as MLH, MSH₂, PMS₁, PMS₂, Mdm2, BRCA₁, and BRCA₂⁴⁴. If
379 the DNA damage can be repaired, the cell will continue to divide into the S phase; if this
380 improvement is not possible, then p53 will induce apoptosis⁴⁵.

381 The second possibility is that the increase in p53 expression is an accumulation of
382 mutant type p53. P53 mutations will cause the protein to be more stable and have a longer
383 half-life than the wild type. This causes the mutant type of p53 protein to be more easily
384 detected immunocytochemically, although positive expression of p53 is not always associated
385 with its gene mutation⁴⁶.

386 P53 mutation is the most common genetic lesion in neoplasms. P53 mutations are
387 associated with increased cellular proliferation and transformation toward malignancy⁴⁷. They
388 will cause changes in the encoded protein products, so they cannot stimulate the transcription
389 of p21 and Bax,⁴¹ thus causing the accumulation of cells with DNA damage, which can turn
390 into cancer cells²².

391 The presence of positive p53 protein expression in the cytoplasm shows that inhibition
392 of Raji cell growth occurs in the G1 phase of the cell cycle. Linamarin from cassava leaves
393 can increase the expression of p53 protein in the cytoplasm compared to the control cells.
394 Linamarin is thought to inhibit cell division in the G1 phase of the cell cycle by increasing the
395 expression of p53 protein in the cytoplasm. According to Groeger,⁴⁸ most of the p53 genes act
396 as 'the guardian of the genome': (1) p53 levels increase rapidly in response to DNA damage,
397 (2) cause cell cycle inhibition during the G1 phase, (3) give cells time to repair DNA damage,

Anticancer Activity of Linamarin on Raji

398 (4) if damage cannot be repaired, p53 will induce programmed cell
399 death (apoptosis). Both wild type and mutant proteins migrate in the cell nucleus known
400 as Nuclear Localization Signals (NLS) that are attached to their primary
401 sequences⁴⁹. According to Baker *et al.*⁵⁰ and Duler *et al.*,⁵¹ p53 wild-type causes growth
402 inhibition in the G1 phase, so that it can be interpreted that in order to enter S phase of the
403 cell, p53 must be inactive.

404 Overall it can be concluded that linamarin from cassava leaves is toxic to Raji cells
405 and can inhibit Raji cell proliferation through increased expression of p53 protein. The
406 expression of p53 protein cannot be distinguished whether p53 is wild or mutant type but
407 seeing the expression of p53 protein in the cytoplasm shows that inhibition of Raji cell
408 proliferation is through cell cycle progression inhibition that occurs in the G1
409 phase. This provides an opportunity for genes that control DNA repair to restore DNA
410 function. The limitation of this study is that it only observes the mechanism of Raji cell
411 proliferation via p53 protein induction, so further research is necessary to discern the
412 pathway(s) for proliferation inhibition through apoptosis induction, p21 expression, DNA
413 repair pathways, and proliferative inhibition locations in the G1 phase of the cell cycle.

414

415 CONCLUSION

416 Linamarin isolated from cassava leaves (*M. esculenta* Cranz) has the potential to be
417 developed as an anticancer agent. Linamarin from cassava leaves (*M. esculenta* Cranz) has
418 cytotoxic activity on Raji cells with IC₅₀ values of 71.865 ± 0.229 µg/ml, antiproliferation
419 activity on Raji cells with a doubling time value of 40.723 hours on linamarin concentration
420 of 62.5 µg/ml and can increase the expression of p53 protein in the nuclei and cytoplasm of
421 Raji cells.

422

Anticancer Activity of Linamarin on Raji

423 **SIGNIFICANCE STATEMENT**

424 Findings from this study could contribute to a better understanding of the mechanism of
425 action of linamarin, which is derived from cassava leaves as an anticancer agent. Future
426 efforts should be directed towards determining the specific cell signaling pathways involved
427 in cancer cell toxicity. It also needs in vivo models in experimental animals and the
428 development of an ideal anti-cancer drug formulation.

429

430 **CONFLICT OF INTEREST STATEMENT**

431 The authors have no conflict of interest or financial interest regarding the results of this
432 research.

433

434 **ACKNOWLEDGEMENTS**

435 The authors would like to thank the Dean of Public Health Faculty of University of
436 Diponegoro who has funded this study through APBN DIPA of Public Health Faculty of
437 University of Diponegoro funding No. 106/UN7.5.9/HK/ 2018, dated May 31, 2018.

438

439 **REFERENCES**

440

- 441 1. Akinpelu, A.O., Amangbo, L.E.F., Olojede, A.O and Oyekale, A.S., 2011. Health
442 implications of cassava production and consumption. J. Agric. Soc .Res.11:118-25.
443 <https://www.ajol.info/index.php/jasr/article/view/73684/64364>
444 2. Adenle., A.A., Aworh, O.C., Akromah, R and Parayilet, G., 2012. Developing GM
445 super cassava for improved health and food security: Future challenges in Africa.
446 Agriculture and Food Security. 1:1-15.
447 [https://agricultureandfoodsecurity.biomedcentral.com/articles/10.1186/2048-7010-](https://agricultureandfoodsecurity.biomedcentral.com/articles/10.1186/2048-7010-1-11)
448 [1-11](https://agricultureandfoodsecurity.biomedcentral.com/articles/10.1186/2048-7010-1-11)
449 3. Ernesto, M., Cardoso, A.P., Nicala, D., Mirione, E and Massaza, F *et al.*, 2002.
450 Persistent konzo and cyanide toxicity from cassava in northern Mozambique. Acta
451 Tropica.82:357-362. [http://biology-](http://biology-assets.anu.edu.au/hosted_sites/CCDN/papers/82_357_362_02.pdf)
452 [assets.anu.edu.au/hosted_sites/CCDN/papers/82_357_362_02.pdf](http://biology-assets.anu.edu.au/hosted_sites/CCDN/papers/82_357_362_02.pdf)
453 4. Sayre, R, Beeching, J.R., Cahoon, E.B., Eges, C and Fauquet, *Cet al.*, 2011. The
454 bio cassava plus program: Biofortification of cassava for sub-Saharan Africa. Annu.

Commented [WU3]: Author is advised to Provide DOI or URL of all listed references.

Anticancer Activity of Linamarin on Raji

- 455 Rev. Plant. Biol. 62:251-72. <https://www.ncbi.nlm.nih.gov/pubmed/21526968>. DOI:
456 10.1146/annurev-arplant-042110-103751.
- 457 5. Alfourjani, W.A., 2005. In vitro anticancer properties of linamarin controlled release
458 from biodegradable poly-lactic co-glycolic acid nanoparticle. Master's Thesis,
459 Universiti Putra Malaysia, Malaysia, pp: 87-90.
460 <http://psasir.upm.edu.my/id/eprint/5996/>
- 461 6. Idibie, C.A., Davids, H and Iyuke, S.E., 2007. Cytotoxicity of purified cassava
462 linamarin to a selected cancer cell lines. Bioproc. Biosyst. Eng. 30: 261-69.
463 <https://www.ncbi.nlm.nih.gov/pubmed/17566787>. DOI: [10.1007/s00449-007-](https://doi.org/10.1007/s00449-007-0122-3)
464 [0122-3](https://doi.org/10.1007/s00449-007-0122-3)
- 465 7. Yusuf, U.F., Ahmadun, F.R., Rosli, R., Iyuke, S.E and Billa, Net al., 2006. An in
466 vitro inhibition of human malignant cell growth of crude water extract of cassava
467 (*Manihot esculenta* Crantz) and commercial linamarin. J. Sci. Tehnol. 28:145-55.
468 https://www.researchgate.net/publication/26469858_An_in_vitro_inhibition_of_hu
469 [man_malignant_cell_growth_of_crude_water_extract_of_cassava_Manihot_esculen](https://www.researchgate.net/publication/26469858_An_in_vitro_inhibition_of_hu)
470 [ta_Crantz_and_commercial_linamarin](https://www.researchgate.net/publication/26469858_An_in_vitro_inhibition_of_hu)
- 471 8. Haque, M.R and Bradbury, J.H., 1999. Preparation of linamarase solution from
472 cassava latex for use in the cassava cyanide kit. Food. Chem. 67: 305-9.
473 <https://eurekamag.com/research/003/239/003239769.php>. DOI: 10.1016/s0308-
474 8146(99)00117-x.
- 475 9. Girald, W., 2012. Toxicity and delivery methods for the
476 linamarase/linamarin/glucose oxidase system, when used against human glioma
477 tumors implanted in the brain of nude rats. Cancer. Lett. 313: 99-107.
478 <https://www.sciencedirect.com/science/article/pii/S030438351100526X?via%3Dihub>
479 [b](https://www.sciencedirect.com/science/article/pii/S030438351100526X?via%3Dihub). DOI: [10.1016/j.canlet.2011.08.029](https://doi.org/10.1016/j.canlet.2011.08.029),
- 480 10. Dorgan, J.F., Sowell, A., Potischman, N., Swanson, C and Miller, Ret al., 1998.
481 Relationship of serum carotenoids, retinol, -tocopherol, and selenium with breast
482 cancer risk: Results from a prospective study. Cancer. Causes. Control. 9:89-97.
483 <https://www.ncbi.nlm.nih.gov/pubmed/9486468>. DOI: [10.1023/a:1008857521992](https://doi.org/10.1023/a:1008857521992)
- 484 11. Cortes, M.L, Garcia-Escudero, V., Hughes, M and Izquierdo, M., 2002. Cyanide
485 bystander effect of the linamarase/linamarin killer-suicide gene therapy system. J.
486 Gene. Med. 4:407-14. <https://www.ncbi.nlm.nih.gov/pubmed/12124983>. DOI:
487 [10.1002/jgm.280](https://doi.org/10.1002/jgm.280)
- 488 12. Dominguez, Eduardo, R., Vazquez-Luna, A., Rodriguez-Landa, J.F and Diaz-Sobac
489 R., 2013. Neurotoxic effect of linamarin in rats associated with cassava
490 (*Manihot esculenta* Crantz) consumption. Food. Chem. Toxicol. 59:230-5.
491 <https://www.ncbi.nlm.nih.gov/pubmed/23778051> DOI: [10.1016/j.fct.2013.06.004](https://doi.org/10.1016/j.fct.2013.06.004)
- 492 13. Duijnhoven, F.J.B., Buebo-De-Mesquita, H.B., Ferrari, P., Jenab, M and
493 Boshuizen, H. Cet al., 2009. Fruit, vegetables and colorectal cancer risk: the European
494 prospective investigation into cancer and nutrition. Am. J. Clin. Nutr. 89:1441-52.
495 <https://www.ncbi.nlm.nih.gov/pubmed/19339391>. DOI: [10.3945/ajcn.2008.27120](https://doi.org/10.3945/ajcn.2008.27120).
496 Epub 2009 Apr 1.
- 497 14. Gloria, N.F., Soares, N., Brand, C., Oliveira, F.L and Borojevic, Ret al., 2014.
498 Lycopene and beta-carotene induce cell-cycle arrest and apoptosis in human breast
499 cancer cell lines. Anticancer. Res. 34: 1377-86.
500 <https://www.sciencedirect.com/science/article/pii/S030438351100526X?via%3Dihub>.
501 DOI: [10.1016/j.canlet.2011.08.029](https://doi.org/10.1016/j.canlet.2011.08.029).
- 502 15. Levrero, M., De Laurenzi, V., Costanzo, A., Gong, J and Wang, J. Yet al., 2000.
503 The p53/p63/p73 family of transcription factors: Overlapping and distinct
504 functions. J. Cell. Sci. 113: 1661-70. <https://www.ncbi.nlm.nih.gov/pubmed/10769197>

- 505 16. Enger, S.M., Longnecker, M.P., Chen, M.J., Lee, E.R and Frankl, H. *Det al.*, 1996.
 506 Dietary intake of specific carotenoids and vitamins A, C, and E, and prevalence of
 507 colorectal adenomas. *Cancer. Epidemiol. Biomarkers. Prev.* 5: 147-53.
 508 <https://pdfs.semanticscholar.org/cf7b/a52044641f18fae1d5320d3aef0e925a6f0b.pdf>
 509 17. Kontek, R., Kontek, B and Grzegorzcyk, K., 2013. Vitamin C modulates DNA
 510 damage induced by hydrogen peroxide in human colorectal adenocarcinoma cell
 511 lines (HT29) estimated by comet assay in vitro. *Arch. Med. Sci.* 9: 1006-12. doi:
 512 10.5114/aoms.2013.39791. <https://www.ncbi.nlm.nih.gov/pubmed/24482643>
 513 18. Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival:
 514 application to proliferation and cytotoxicity assays. *J. Immunol. Methods.* 65: 55-63.
 515 19. Itharat, A and Ooraikul, B., 2007. Research on Thai medical plants for cancer
 516 treatment. *Adv. Med. Plant. Res.* 37: 287-317.
 517 <https://www.ncbi.nlm.nih.gov/pubmed/6606682> DOI:10.1016/0022-1759(83)90303-
 518 4
 519 20. He, Y., Zhu, Q., Chen, M., Huang, Q and Wang W *et al.*, 2016. The changing 50%
 520 inhibitory concentration (IC₅₀) of cisplatin: a pilot study on the artifacts of the MTT
 521 assay and the precise measurement of density-dependent chemoresistance in ovarian
 522 cancer. *Oncotarget.* 7: 70803-21. <https://www.ncbi.nlm.nih.gov/pubmed/27683123>
 523 DOI: 10.18632/oncotarget.12223.
 524 21. Jorgensen, K., Morant, A.V., Morant, M., Jensen, N.B and Olsen, C.E., *et al.*, 2011.
 525 Biosynthesis of the cyanogenic glucosides linamarin and lotaustralin in cassava:
 526 isolation, biochemical characterization, and expression pattern of CYP71E7, the
 527 oxime-metabolizing cytochrome P450 enzyme. *Plant. Physiol.* 155: 282-92.
 528 <https://www.ncbi.nlm.nih.gov/pubmed/21045121>. DOI: 10.1104/pp.110.164053.
 529 Epub 2010 Nov 2.
 530 22. Lane, D.P., Cheok, C.F and Lain, S., 2010. P53 based cancer therapy, Cold Spring
 531 Harbor. *Perspect. Biol.* 2: a001222. [https://pubmed.ncbi.nlm.nih.gov/20463003-p53-](https://pubmed.ncbi.nlm.nih.gov/20463003-p53-based-cancer-therapy/)
 532 [based-cancer-therapy/](https://pubmed.ncbi.nlm.nih.gov/20463003-p53-based-cancer-therapy/). DOI: 10.1101/cshperspect.a001222
 533 23. Afsar, T., Trembley, J.H., Salomon, C.E., Razak, S and Khan, M.R., 2016. Growth
 534 inhibition and apoptosis in cancer cells induced by polyphenolic compounds of
 535 *Acacia hydaspica*: Involvement of multiple signal transduction pathways. *Sci. Rep.*
 536 6: 1-12. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791679/>
 537 DOI: 10.1038/srep23077
 538 24. Lehmann, B.D., Bauer, J.A., Chen, X., Sanders, M.E and Chakravanthy, A. *Bet*
 539 *al.*, 2011. Pietenpol JA. Identification of human triple-negative breast cancer
 540 subtypes and preclinical models for selection of targeted therapies. *J. Clin. Invest.*
 541 121: 2750-67. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3127435/>
 542 DOI: 10.1172/JCI45014
 543 25. Khan, N., Afaq, F., Saleem, M., Ahmad, N and Mukhtar, H., 2006. Targeting
 544 multiple signaling pathways by green tea polyphenol (–)-epigallocatechin-3-gallate.
 545 *Cancer. Res.* 66:2500-5. [https://pubmed.ncbi.nlm.nih.gov/16510563-targeting-](https://pubmed.ncbi.nlm.nih.gov/16510563-targeting-multiple-signaling-pathways-by-green-tea-polyphenol-epigallocatechin-3-gallate/)
 546 [multiple-signaling-pathways-by-green-tea-polyphenol-epigallocatechin-3-gallate/](https://pubmed.ncbi.nlm.nih.gov/16510563-targeting-multiple-signaling-pathways-by-green-tea-polyphenol-epigallocatechin-3-gallate/)
 547 DOI: 10.1158/0008-5472.CAN-05-3636
 548 26. Ghate, N.B., Hazra, B., Sarkar, R and Mandal N., 2014. Heartwood extract of
 549 *Acacia catechu* induces apoptosis in human breast carcinoma by altering bax/bcl-2
 550 ratio. *Pharmacogn. Mag.* 10:27-33 [https://pubmed.ncbi.nlm.nih.gov/24695415-](https://pubmed.ncbi.nlm.nih.gov/24695415-heartwood-extract-of-acacia-catechu-induces-apoptosis-in-human-breast-carcinoma-by-altering-baxbcl-2-ratio/)
 551 [heartwood-extract-of-acacia-catechu-induces-apoptosis-in-human-breast-carcinoma-](https://pubmed.ncbi.nlm.nih.gov/24695415-heartwood-extract-of-acacia-catechu-induces-apoptosis-in-human-breast-carcinoma-by-altering-baxbcl-2-ratio/)
 552 [by-altering-baxbcl-2-ratio/](https://pubmed.ncbi.nlm.nih.gov/24695415-heartwood-extract-of-acacia-catechu-induces-apoptosis-in-human-breast-carcinoma-by-altering-baxbcl-2-ratio/). DOI: 10.4103/0973-1296.126654
 553 27. Catz, S.D and Johnson, J.L., 2001. Transcriptional regulation of bcl-2 by nuclear
 554 factor kappa B and its significance in prostate cancer. *Oncogene.* 20: 7342-51.


- 555 [https://pubmed.ncbi.nlm.nih.gov/11704864-transcriptional-regulation-of-bcl-2-by-](https://pubmed.ncbi.nlm.nih.gov/11704864-transcriptional-regulation-of-bcl-2-by-nuclear-factor-kappa-b-and-its-significance-in-prostate-cancer/)
556 [nuclear-factor-kappa-b-and-its-significance-in-prostate-cancer/](https://pubmed.ncbi.nlm.nih.gov/11704864-transcriptional-regulation-of-bcl-2-by-nuclear-factor-kappa-b-and-its-significance-in-prostate-cancer/).
557 DOI: [10.1038/sj.onc.1204926](https://doi.org/10.1038/sj.onc.1204926)
- 558 28. Bolhasasni, A., Khavari, A and Bathaie SZ., 2001. Saffron and natural
559 carotenoids: biochemical activities and anti-tumor effects. *Biochim. Biophys.*
560 *Acta.* 1845: 20-30. [https://pubmed.ncbi.nlm.nih.gov/24269582-saffron-and-](https://pubmed.ncbi.nlm.nih.gov/24269582-saffron-and-natural-carotenoids-biochemical-activities-and-anti-tumor-effects/)
561 [natural-carotenoids-biochemical-activities-and-anti-tumor-effects/](https://pubmed.ncbi.nlm.nih.gov/24269582-saffron-and-natural-carotenoids-biochemical-activities-and-anti-tumor-effects/).
562 DOI: [10.1016/j.bbcan.2013.11.001](https://doi.org/10.1016/j.bbcan.2013.11.001)
- 563 29. Duarte, T.L and Lunec, J., 2005. Review: When is an antioxidant not an
564 antioxidant? A review of novel actions and reactions of vitamin C. *Free. Radic. Res.*
565 39:671-86. [https://pubmed.ncbi.nlm.nih.gov/16036346-review-when-is-an-](https://pubmed.ncbi.nlm.nih.gov/16036346-review-when-is-an-antioxidant-not-an-antioxidant-a-review-of-novel-actions-and-reactions-of-vitamin-c/)
566 [antioxidant-not-an-antioxidant-a-review-of-novel-actions-and-reactions-of-vitamin-](https://pubmed.ncbi.nlm.nih.gov/16036346-review-when-is-an-antioxidant-not-an-antioxidant-a-review-of-novel-actions-and-reactions-of-vitamin-c/)
567 [c/](https://pubmed.ncbi.nlm.nih.gov/16036346-review-when-is-an-antioxidant-not-an-antioxidant-a-review-of-novel-actions-and-reactions-of-vitamin-c/). DOI: [10.1080/10715760500104025](https://doi.org/10.1080/10715760500104025)
- 568 30. Verma, R.S., Mhta, A and Srivastava, N., 2007. In vivo chlorpyrifos induced
569 oxidative stress: A enuation by antioxidant vitamins. *Pestic. Biochem. Physiol.*
570 88:191-6.
571 <https://www.sciencedirect.com/science/article/abs/pii/S0048357506001854>.
572 <https://doi.org/10.1016/j.pestbp.2006.11.002>
- 573 31. Szarka, A., Tomassovics, B and Bánhegyi, G., 2012. The ascorbate-gluthathione-
574 tocopherol triad in abiotic stress response. *Intern. J. Mol. Sci.* 13:4458-83.
575 [https://pubmed.ncbi.nlm.nih.gov/22605990-the-ascorbate-gluthathione-tocopherol-](https://pubmed.ncbi.nlm.nih.gov/22605990-the-ascorbate-gluthathione-tocopherol-triad-in-abiotic-stress-response/)
576 [triad-in-abiotic-stress-response/](https://pubmed.ncbi.nlm.nih.gov/22605990-the-ascorbate-gluthathione-tocopherol-triad-in-abiotic-stress-response/). DOI: [10.3390/ijms13044458](https://doi.org/10.3390/ijms13044458)
- 577 32. Bindhumol, V., Chitra, K.C and Mathur, P.P., 2003. Bhisphenol A induces reactive
578 oxygen species generation in the liver of male rats. *Toxicology.* 188:117-24.
579 [https://pubmed.ncbi.nlm.nih.gov/12767684-bisphenol-a-induces-reactive-oxygen-](https://pubmed.ncbi.nlm.nih.gov/12767684-bisphenol-a-induces-reactive-oxygen-species-generation-in-the-liver-of-male-rats/)
580 [species-generation-in-the-liver-of-male-rats/](https://pubmed.ncbi.nlm.nih.gov/12767684-bisphenol-a-induces-reactive-oxygen-species-generation-in-the-liver-of-male-rats/). DOI: [10.1016/s0300-483x\(03\)00056-8](https://doi.org/10.1016/s0300-483x(03)00056-8)
- 581 33. Winkler, B.S., Orselli, S.M and Rex, T.S., 1994. The redox couple between
582 glutathione and ascorbic acid: A chemical and physiological perspective. *Free.*
583 *Radic Biol. Med.* 17: 333-49. [https://pubmed.ncbi.nlm.nih.gov/8001837-the-redox-](https://pubmed.ncbi.nlm.nih.gov/8001837-the-redox-couple-between-gluthathione-and-ascorbic-acid-a-chemical-and-physiological-perspective/)
584 [couple-between-gluthathione-and-ascorbic-acid-a-chemical-and-physiological-](https://pubmed.ncbi.nlm.nih.gov/8001837-the-redox-couple-between-gluthathione-and-ascorbic-acid-a-chemical-and-physiological-perspective/)
585 [perspective/](https://pubmed.ncbi.nlm.nih.gov/8001837-the-redox-couple-between-gluthathione-and-ascorbic-acid-a-chemical-and-physiological-perspective/). DOI: [10.1016/0891-5849\(94\)90019-1](https://doi.org/10.1016/0891-5849(94)90019-1)
- 586 34. Griffiths, H.R and Lunec, J., 2001. Ascorbic acid in the 21st century-more than a
587 simple antioxidant. *Environ. Toxicol. Pharm.* 10:173-82.
588 [https://pubmed.ncbi.nlm.nih.gov/21782574-ascorbic-acid-in-the-21st-century-more-](https://pubmed.ncbi.nlm.nih.gov/21782574-ascorbic-acid-in-the-21st-century-more-than-a-simple-antioxidant/)
589 [than-a-simple-antioxidant/](https://pubmed.ncbi.nlm.nih.gov/21782574-ascorbic-acid-in-the-21st-century-more-than-a-simple-antioxidant/). DOI: [10.1016/s1382-6689\(01\)00081-3](https://doi.org/10.1016/s1382-6689(01)00081-3)
- 590 35. Finlay, C.A., Hinds, PW and Levine, A.J., 1999. The p53 protooncogene can act as
591 a suppressor of transformation. *Cell.* 57: 1083-93.
592 [https://pubmed.ncbi.nlm.nih.gov/2525423-the-p53-proto-oncogene-can-act-as-a-](https://pubmed.ncbi.nlm.nih.gov/2525423-the-p53-proto-oncogene-can-act-as-a-suppressor-of-transformation/)
593 [suppressor-of-transformation/](https://pubmed.ncbi.nlm.nih.gov/2525423-the-p53-proto-oncogene-can-act-as-a-suppressor-of-transformation/). DOI: [10.1016/0092-8674\(89\)90045-7](https://doi.org/10.1016/0092-8674(89)90045-7)
- 594 36. Oraiopoulou, M.E., Tzamali, E., Tzedakis, G., Vakis, A., and Papamatheakis J, *et*
595 *al.* 2017. In vitro/in silico study on the role of doubling time heterogeneity among
596 primary glioblastoma cell lines. *Biomed .Res. Int.* 1-12.
597 <https://www.hindawi.com/journals/bmri/2017/8569328/>.
598 <https://doi.org/10.1155/2017/8569328>
- 599 37. Atuegwu, N.C., Arlinghaus, L.R., Li, X., Chakravarthy, A.B and Abramson, V.G *et*
600 *al.*, 2013. Parameterizing the logistic model of tumor growth by DW-MRI and
601 DCE-MRI data to predict treatment response and changes in breast cancer
602 cellularity during neoadjuvant chemotherapy. *Transl. Oncol.* 6:256-64.
603 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660793/>. DOI: [10.1593/tlo.13130](https://doi.org/10.1593/tlo.13130)

- 604 38. Bertuzzi, A., Gandol, A., Sinisgalli, C., Starace, G and Ubezio, P., 1997. Cell loss
605 and the concept of potential doubling time. *Cytometry*. 29:34-40.
606 [https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291097-](https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291097-0320%2819970901%2929%3A1%3C34%3A%3AAID-CYTO3%3E3.0.CO%3B2-D)
607 [0320%2819970901%2929%3A1%3C34%3A%3AAID-CYTO3%3E3.0.CO%3B2-](https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291097-0320%2819970901%2929%3A1%3C34%3A%3AAID-CYTO3%3E3.0.CO%3B2-D)
608 [D.](https://doi.org/10.1002/(SICI)1097-0320(19970901)29:1<34::AID-CYTO3>3.0.CO;2-D) [https://doi.org/10.1002/\(SICI\)1097-0320\(19970901\)29:1<34::AID-](https://doi.org/10.1002/(SICI)1097-0320(19970901)29:1<34::AID-CYTO3>3.0.CO;2-D)
609 [CYTO3>3.0.CO;2-D](https://doi.org/10.1002/(SICI)1097-0320(19970901)29:1<34::AID-CYTO3>3.0.CO;2-D)
610 39. Lowe, S.W., 1999. Activation of p53 by oncogenes. *Endocr. Relat. Cancer*. 6: 45-8.
611 <https://pubmed.ncbi.nlm.nih.gov/10732786-activation-of-p53-by-oncogenes/>
612 DOI: [10.1677/erc.0.0060045](https://pubmed.ncbi.nlm.nih.gov/10732786-activation-of-p53-by-oncogenes/)
613 40. Rivlin, N., Ran, Brosh, R., Oren, M and Rotter, V., 2011. Mutations in the p53
614 tumor suppressor gene: Important milestones at the various steps of tumorigenesis.
615 *Genes. Cancer*. 2: 466-74.
616 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3135636/>.
617 DOI: [10.1177/1947601911408889](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3135636/)
618 41. Sugermaun, P.B and Savage, N.W., 1999. Current concepts in oral cancer.
619 *Aust.Dent. J.* 44: 147-56. [https://pubmed.ncbi.nlm.nih.gov/10592559-current-](https://pubmed.ncbi.nlm.nih.gov/10592559-current-concepts-in-oral-cancer/)
620 [concepts-in-oral-cancer/](https://pubmed.ncbi.nlm.nih.gov/10592559-current-concepts-in-oral-cancer/). DOI: [10.1111/j.1834-7819.1999.tb00216.x](https://pubmed.ncbi.nlm.nih.gov/10592559-current-concepts-in-oral-cancer/)
621 42. Petitjean, A., Mathe, E., Kato, S., Ishioka, C and Tavtigian, S. *Vet al.*, 2007. Impact
622 of mutant p53 functional properties on TP53 mutation patterns and tumor
623 phenotype: lessons from recent developments in the IARC TP53 database. *Hum.*
624 *Mutat.* 28:622-9. [https://pubmed.ncbi.nlm.nih.gov/17311302-impact-of-mutant-p53-](https://pubmed.ncbi.nlm.nih.gov/17311302-impact-of-mutant-p53-functional-properties-on-tp53-mutation-patterns-and-tumor-phenotype-lessons-from-recent-developments-in-the-iarc-tp53-database/)
625 [functional-properties-on-tp53-mutation-patterns-and-tumor-phenotype-lessons-](https://pubmed.ncbi.nlm.nih.gov/17311302-impact-of-mutant-p53-functional-properties-on-tp53-mutation-patterns-and-tumor-phenotype-lessons-from-recent-developments-in-the-iarc-tp53-database/)
626 [from-recent-developments-in-the-iarc-tp53-database/](https://pubmed.ncbi.nlm.nih.gov/17311302-impact-of-mutant-p53-functional-properties-on-tp53-mutation-patterns-and-tumor-phenotype-lessons-from-recent-developments-in-the-iarc-tp53-database/). DOI: [10.1002/humu.20495](https://pubmed.ncbi.nlm.nih.gov/17311302-impact-of-mutant-p53-functional-properties-on-tp53-mutation-patterns-and-tumor-phenotype-lessons-from-recent-developments-in-the-iarc-tp53-database/)
627 43. Hainaut, P and Hollstein, M., 2000. P53 and human cancer: the first ten thousand
628 mutations. *Adv. Cancer. Res.* 77:81-137.
629 [https://pubmed.ncbi.nlm.nih.gov/10549356-p53-and-human-cancer-the-first-ten-](https://pubmed.ncbi.nlm.nih.gov/10549356-p53-and-human-cancer-the-first-ten-thousand-mutations/)
630 [thousand-mutations/](https://pubmed.ncbi.nlm.nih.gov/10549356-p53-and-human-cancer-the-first-ten-thousand-mutations/). DOI: [10.1016/s0065-230x\(08\)60785-x](https://pubmed.ncbi.nlm.nih.gov/10549356-p53-and-human-cancer-the-first-ten-thousand-mutations/)
631 44. Schlomm, T., Iwers, L., Kirstein, P., Jessen, B and Kollermann *Jet al.*, 2008.
632 Clinical significance of p53 alterations in surgically treated prostate cancers. *Mod.*
633 *Pathol.* 21:1371-8. [https://pubmed.ncbi.nlm.nih.gov/18552821-clinical-significance-](https://pubmed.ncbi.nlm.nih.gov/18552821-clinical-significance-of-p53-alterations-in-surgically-treated-prostate-cancers/)
634 [of-p53-alterations-in-surgically-treated-prostate-cancers.](https://pubmed.ncbi.nlm.nih.gov/18552821-clinical-significance-of-p53-alterations-in-surgically-treated-prostate-cancers/)
635 DOI: [10.1038/modpathol.2008.104](https://pubmed.ncbi.nlm.nih.gov/18552821-clinical-significance-of-p53-alterations-in-surgically-treated-prostate-cancers/)
636 45. Macdonald, F and Ford, C.H.J., 1997. *Molecular biology of cancer*, Bios. Oxford:
637 Scientific Publishers, pp: 53-60. <https://archive.org/details/molecularbiology00fmac>
638 46. Nozaki, M., Tada, M., Kobayashi, H., Zhang, C.L and Sawamura, Y *et al.*, 1999.
639 Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis
640 and progression. *Neuro. Oncol.* 1:124-37.
641 <https://www.ncbi.nlm.nih.gov/pubmed/11550308>. DOI: [10.1093/neuonc/1.2.124](https://www.ncbi.nlm.nih.gov/pubmed/11550308).
642 47. Oren, M and Rotter, V., 2010. Mutant p53 gain-of-function in cancer. *Cold Spring*
643 *Harb. Perspect. Biol.* 2:a001107. <https://www.ncbi.nlm.nih.gov/pubmed/20182618>.
644 DOI: [10.1101/cshperspect.a001107](https://www.ncbi.nlm.nih.gov/pubmed/20182618).
645 48. Groeger, A.M., Esposito, V., De Luca, A., Cassandro, R and Tonini, G *et al.*, 2004.
646 Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-xL
647 in resected non-small-cell lung cancers. *Histopathology.* 44:54-63.
648 <https://www.ncbi.nlm.nih.gov/pubmed/14717670>. DOI: [10.1111/j.1365-](https://www.ncbi.nlm.nih.gov/pubmed/14717670)
649 [2559.2004.01750.x](https://www.ncbi.nlm.nih.gov/pubmed/14717670)
650 49. Shaulsky, G., Goldfinger, N., Tosky, M.S., Levine, A.J and Rotter, V., 1991.
651 Nuclear localization is essential for the activity of p53 protein. *Oncogene.* 6: 2055-
652 65. [https://pubmed.ncbi.nlm.nih.gov/1719467-nuclear-localization-is-essential-for-](https://pubmed.ncbi.nlm.nih.gov/1719467-nuclear-localization-is-essential-for-the-activity-of-p53-protein/)
653 [the-activity-of-p53-protein/](https://pubmed.ncbi.nlm.nih.gov/1719467-nuclear-localization-is-essential-for-the-activity-of-p53-protein/)

Anticancer Activity of Linamarin on Raji

654 50. Burck, K.B., Liu, E. and Larick, J.W., 1988. *Oncogenes: An introduction to the*
655 *concept of cancer genes*, New York: Springer-Verlag, pp: 87-99. ISBN
656 9781461237181 (online) 9780387964232 (print). DOI: 10.1007/978-1-4612-3718-1
657 51. McManus, E.J and Alessi, D.R., 2004. Cancer, oncogenes and signal transduction.
658 *Genome. Biol.*5:332. [https://genomebiology.biomedcentral.com/articles/10.1186/gb-](https://genomebiology.biomedcentral.com/articles/10.1186/gb-2004-5-7-332)
659 [2004-5-7-332](https://genomebiology.biomedcentral.com/articles/10.1186/gb-2004-5-7-332)
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696


Anticancer Activity of Linamarin on Raji



A. Raji control cell (without treatment)



B. Raji cells with linamarin 32.5µg/ml



C. Raji cells with linamarin 62.5µg/ml

697

698 **Fig.1.** Microscopic photo of Raji cells with treatment of linamarin 32.5 and 62.5 µg/ml and
699 control (without treatment) with immunocytochemical staining (magnification 400x).

700 Information: (i) positive cells with expression of p53 protein have brown nuclei or cytoplasm;

701 (ii) cells that are negative for p53 protein expression have purple nuclei or cytoplasm.

702

703

704

705

706

707

708

709

Commented [WU4]: Author is advised to label the figure 1 correctly by which a reader can easily understand the results obtained in figure 1.

Anticancer Activity of Linamarin on Raji

710 **Table: 1.** Average number of living cells vs. percentage of Raji cell inhibition after
 711 administration of various concentrations of linamarin

712

No	Linamarin concentration µg/ml	Absorbance				Average	% of Raji cell inhibition± SEM
		I	II	III	IV		
1	31.25	0.643	0.565	0.678	0.462	0.587	27.194 ± 0.096*
2	62.5	0.381	0.565	0.453	0.323	0.431	46.605 ± 0.104*
3	125	0.076	0.035	0.553	0.539	0.301	62.698 ± 0.284*
4	250	0.043	0.033	0.457	0.414	0.237	70.636 ± 0.230*
5	500	0.045	0.121	0.302	0.189	0.164	79.628 ± 0.109*
6	1000	0.021	0.026	0.019	0.013	0.020	97.550 ± 0.005*
7	Cell control	0.794	0.761	0.865	0.805	0.806	0.000 ± 0.043
8	Media control	0.043	0.033	0.031	0.033	0.035	0.000 ± 0.005

713 * p <0.05 with one-way ANOVA test; SEM: Standard error of the mean

714

715 **Table: 2.** Doubling time of Raji cells after treatment with various concentrations of linamarin
 716 vs. control

Treatment	The hours of Raji cell lives				The equation between incubation time vs. number of living cells	Doubling time (hours)
	0	24	48	72		
Control	20.000	48.444	84.813	131.879	Y = 0.0113x + 4.345	22.749
Linamarin 62.50 µg/ml	20.000	31.482	47.458	63.491	Y = 0.0007x + 4.317	40.723
Linamarin 31.25 µg/ml	20.000	42.631	66.391	89.366	Y = 0.0089x + 4.354	27.804
Linamarin 15.63 µg/ml	20.000	51.046	69.236	89.500	Y = 0.0087x + 4.387	24.65

717

718

719

720

721

Anticancer Activity of Linamarin on Raji

722 **Table: 3.** Percentage of p53 protein expression on Raji cell control and linamarin
 723 concentrations of 62.5 µg/ml and 31.25 µg/ml

Replication	Expression of p53 protein on Raji cells					
	Control		Linamarin 62.5µg/ml		Linamarin 31.25 µg/ml	
	Positive	Negative	Positive	Negative	Positive	Negative
I	12	88	86	14	40	60
II	8	92	73	27	45	55
III	14	86	73	27	39	61
IV	7	93	78	22	36	64
Total	41	359	310	90	160	240
Percentage (%) ± SEM	10.25 ± 1.65	89.75 ± 1.65	77.5 ± 3.07	22.5 ± 3.07	40 ± 1.87	60 ± 1.87

724 SEM: Standard error of the mean

725

726

727 **Table: 4.** Location of p53 protein expression of Raji cells control and linamarin
 728 concentrations of 62.5 µg/ml and 31.25 µg/ml

Treatment	Position of p53 protein expression of Raji cells									
	Nucleus					Cytoplasm				
	I	II	III	IV	Mean (%) ± SEM	I	II	III	IV	Mean (%) ± SEM
Control	9	7	8	9	80.49 ± 0.48	2	2	2	2	19.51 ± 0.00
Linamarin 62.5 µg/ml	76	65	67	70	89.68 ± 2.40	7	7	8	10	10.32 ± 0.71
Linamarin 32.25 µg/ml	33	26	30	33	76.25 ± 1.66	7	9	12	10	23.75 ± 1.04

731 SEM: Standard error of the mean

732
 733
 734
 735
 736
 737
 738
 739
 740



adekutari pratiwi <adekutari25@gmail.com>

Fwd: Transaction confirmation

1 pesan

dwi sutiningsih <dwisuti98@gmail.com>
Kepada: adekutari25@gmail.com

21 September 2020 09.29

----- Forwarded message -----

Dari: **Science Alert** <no-reply@telr.com>

Date: Kam, 6 Feb 2020 21:26

Subject: Transaction confirmation

To: <dwisuti98@gmail.com>

Transaction confirmation

Science Alert

Transaction reference:	030024866355
Transaction type:	Sale
Amount:	\$325.00
Description:	Publication / Processing Charges
Time:	6:26 PM on Thursday the 6th of February, 2020
Authorisation Code:	003470
Card:	Visa Credit ending 4319

Please retain this receipt for your records.

For more information, please visit <http://sciencealert.ae/> or contact sarwarm@sciencealert.ae



adekutari pratiwi <adekutari25@gmail.com>

Fwd: 101171-IJCR-AJ - Request for Payment

1 pesan

dwi sutiningsih <dwisuti98@gmail.com>
Kepada: adekutari25@gmail.com

21 September 2020 09.28

----- Forwarded message -----

Dari: **Science Alert** <support@scialert.com>
Date: Kam, 6 Feb 2020 22:33
Subject: 101171-IJCR-AJ - Request for Payment
To: Dwi Sutiningsih <dwisuti98@gmail.com>

Dear Ms. Dwi Sutiningsih

This is with regard to your submitted manuscript, 101171-IJCR-AJ, titled Cytotoxic and Antiproliferative Activity and Induction of p53 Protein on Raji Cells after Treatment with Linamarin from Cassava Leaves (*Manihot esculenta* Cranz), submitted to International Journal of Cancer Research on 13 January, 2020 for consideration as a Research Article.

The above mentioned manuscript has been finally accepted by the Reviewer for publication in International Journal of Cancer Research as Research Article. You may download the final acceptance letter after log in to your account with User ID dwisuti98@gmail.com.

Before we can continue with final production, it is mandatory to pay Article Processing Charges. All articles published in our journals are open access and freely available online, immediately upon publication. This is made possible by an article-processing charge (APC) that covers the range of publishing services we provide. This includes provision of online tools for editors and authors, article production and hosting, liaison with abstracting and indexing services, and customer services. The APC, payable when your manuscript is editorially accepted and before publication, is charged to either you, or your funder, institution or employer.

You may download the invoice after log in to your account with User ID: dwisuti98@gmail.com.

If you have forgot your password, you may retrieve your password from the following link by providing your User ID dwisuti98@gmail.com.

http://scialert.com/forgot_password.php

Therefore, It is requested to please pay the Article Processing Charges urgently so that we may send your article to the production department for final publication.

We look forward to hearing from you.

Regard
Academic Editor
International Journal of Cancer Research



adekutari pratiwi <adekutari25@gmail.com>

Fwd: Status has been changed for your article No. 101171-IJCR-AJ

1 pesan

dwi sutiningsih <dwisuti98@gmail.com>
Kepada: adekutari25@gmail.com

21 September 2020 09.27

----- Forwarded message -----

Dari: **Science Alert** <no-reply@scialert.com>

Date: Sel, 14 Apr 2020 17:50

Subject: Status has been changed for your article No. 101171-IJCR-AJ

To: Dwi Sutiningsih <dwisuti98@gmail.com>

Dear Dwi Sutiningsih,

Status of your above mentioned manuscript has been changed. Current status of your manuscript is as under:

Published: Manuscript has been published in [International Journal of Cancer Research](#)

For further information, please logon the system at <http://www.scialert.com/login.php> with your user id and password.

Best Regards
Science Alert Support Team